Program
galunisertib
Also written as “Galunisertib”, “LY2157299” and “Galunisertib + Nerandomilast Combination”.
Its studies are mostly in Carcinoma, Hepatocellular · Pancreatic Neoplasms · Neoplasms · Amyotrophic Lateral Sclerosis · Glioblastoma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 150 open or running | phase 3since Dec 6, 2013 | Nov 1, 2010 | none ahead |
| Gipfel Life Sciences | 11 open or running | phase 3since Jan 2, 2026 | Jan 2, 2026 | Jun 30, 2027phase 3 · NCT07321860 |
Also a collaborator on its studies: Bristol-Myers Squibb and AstraZeneca.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Nov 1, 2010.
- Jun 9, 2011Phase 2 study in NeoplasmsEli Lilly · NCT01373164 · 170 enrolled · United States, Belgium, France and more
- Apr 19, 2012Phase 2 study in GlioblastomaEli Lilly · NCT01582269 · 158 enrolled · United States, Australia, Belgium and more
- Sep 6, 2012Phase 1 study in GliomaEli Lilly · NCT01682187 · 66 enrolled · United States, Spain
- Nov 5, 2012Phase 1 study in NeoplasmsEli Lilly · NCT01722825 · 12 enrolled · Japan
- Dec 6, 2012Phase 1 study in Healthy VolunteersEli Lilly · NCT01746004 · 8 enrolled · United States
- Oct 16, 2013Phase 1 study in Healthy VolunteersEli Lilly · NCT01965808 · 16 enrolled · United States
- Dec 6, 2013Phase 3 study in Myelodysplastic SyndromesEli Lilly · NCT02008318 · 43 enrolled · Germany, Italy, Spain
- May 14, 2014Phase 1 study in Pancreatic NeoplasmsEli Lilly · NCT02154646 · 6 enrolled · Japan
- Jun 12, 2014Phase 2 study in Carcinoma, HepatocellularEli Lilly · NCT02178358 · 132 enrolled · China, Hong Kong, Korea, Republic of and more
- Sep 11, 2014Phase 1 study in Carcinoma, HepatocellularEli Lilly · NCT02240433 · 9 enrolled · Japan
- Nov 26, 2014Phase 1 study in NeoplasmsEli Lilly · NCT02304419 · 10 enrolled · United States
- Apr 17, 2015Phase 2 study in Solid TumorEli Lilly · NCT02423343 · 41 enrolled · United States, Spain
- Apr 6, 20162 phase 1 studiesEli Lilly · NCT02734160, NCT02752919
- Jan 2, 2026Gipfel Life Sciences's first study: phase 3 study in Amyotrophic Lateral SclerosisNew to Gipfel Life SciencesGipfel Life Sciences · NCT07321860 · 60 planned
Ahead
- Jun 30, 2027Primary completion: phase 3 study in Amyotrophic Lateral SclerosisGipfel Life Sciences · NCT07321860
TargetBeta
“An orally available, small molecule antagonist of the tyrosine kinase transforming growth factor-beta (TGF-b) receptor type 1 (TGFBR1), ”NCIt, by rule
“TGF-beta receptor type I inhibitor”ChEMBL 37, by rule
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07321860Amyotrophic Lateral Sclerosis | 3 | Not yet recruiting | Gipfel Life Sciences | Jun 30, 2027 | 60 |
| NCT02752919Healthy · United Kingdom | 1 | Completed | Eli Lilly | Jun 2016 | 40 |
| NCT02734160Pancreatic Neoplasms · United States, France, Italy and more | 1 | Completed | Eli Lilly | Aug 2, 2018 | 37 |
| NCT02423343Solid Tumor · United States, Spain | 2 | Completed | Eli Lilly | Dec 13, 2018 | 41 |
| NCT02304419Neoplasms · United States | 1 | Completed | Eli Lilly | Aug 2016 | 10 |
| NCT02240433Carcinoma, Hepatocellular · Japan | 1 | Completed | Eli Lilly | Jul 19, 2017 | 9 |
| NCT02178358Carcinoma, Hepatocellular · China, Hong Kong, Korea, Republic of and more | 2 | Completed | Eli Lilly | Jun 30, 2017 | 132 |
| NCT02154646Pancreatic Neoplasms · Japan | 1 | Completed | Eli Lilly | Sep 2014 | 6 |
| NCT02008318Myelodysplastic Syndromes · Germany, Italy, Spain | 3 | Completed | Eli Lilly | Mar 2016 | 43 |
| NCT01965808Healthy Volunteers · United States | 1 | Completed | Eli Lilly | Nov 2013 | 16 |
| NCT01746004Healthy Volunteers · United States | 1 | Completed | Eli Lilly | Feb 2013 | 8 |
| NCT01722825Neoplasms · Japan | 1 | Completed | Eli Lilly | Jun 2014 | 12 |
| NCT01682187Glioma · United States, Spain | 1 | Completed | Eli Lilly | May 22, 2012 | 66 |
| NCT01582269Glioblastoma · United States, Australia, Belgium and more | 2 | Completed | Eli Lilly | Jul 26, 2014 | 158 |
| NCT01373164Neoplasms · United States, Belgium, France and more | 2 | Completed | Eli Lilly | Nov 2015 | 170 |
| NCT01246986Carcinoma, Hepatocellular · United States, Australia, France and more | 2 | Completed | Eli Lilly | Jun 6, 2019 | 204 |
How it is read
Names in the registry
- “Galunisertib”, 7 entries
- “LY2157299”, 7 entries
- “Galunisertib + Nerandomilast Combination”, 1 entry
- “[^14C]-LY2157299”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 4 studies
- Pancreatic Neoplasms, 2 studies
- Neoplasms, 2 studies
- Amyotrophic Lateral Sclerosis, 1 study
- Glioblastoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.